DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

whitePaper | July 7, 2023

Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need